{"nctId":"NCT01204294","briefTitle":"Comprehensive Add on Study in Japan","startDateStruct":{"date":"2010-09"},"conditions":["Diabetes Mellitus, Type 2"],"count":574,"armGroups":[{"label":"Bigu+Lina","type":"EXPERIMENTAL","interventionNames":["Drug: Linagliptin"]},{"label":"Glin+Lina","type":"EXPERIMENTAL","interventionNames":["Drug: Linagliptin"]},{"label":"Glit+Lina","type":"EXPERIMENTAL","interventionNames":["Drug: Linagliptin"]},{"label":"SU+Lina","type":"EXPERIMENTAL","interventionNames":["Drug: Linagliptin"]},{"label":"A-GI+Lina","type":"EXPERIMENTAL","interventionNames":["Drug: Linagliptin"]},{"label":"SU+Met","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin"]},{"label":"A-GI+Met","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin"]}],"interventions":[{"name":"Linagliptin","otherNames":[]},{"name":"Linagliptin","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Metformin","otherNames":[]},{"name":"Linagliptin","otherNames":[]},{"name":"Linagliptin","otherNames":[]},{"name":"Linagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of type 2 diabetes mellitus\n2. Male and female patients on diet and exercise regimen who are treated with one antidiabetic drug\n\nExclusion criteria:\n\n1. Myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism\n2. Impaired hepatic function\n3. Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined as estimated glomerular filtration rate \\<30 ml/min (severe renal impairment) at Visit 1, Biguanide group: renal failure or renal impairment defined as estimated glomerular filtration rate \\<60 ml/min (moderate renal impairment) at Visit 1\n4. Treatment with anti-obesity drugs","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of Adverse Events (AEs)","description":"The number of patient with any AEs, patients with severe AE, patients with AEs leading to discontinuation of trial drug, and patients with Hypoglycaemic events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"62","spread":null},{"groupId":"OG003","value":"114","spread":null},{"groupId":"OG004","value":"71","spread":null},{"groupId":"OG005","value":"44","spread":null},{"groupId":"OG006","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"1","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"8","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"4","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"21","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"10","spread":null},{"groupId":"OG006","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Glycosylated Haemoglobin A1c (HbA1c)","description":"The change from baseline in HbA1c after 52 weeks of treatment. When the HbA1c after 52 weeks treatment was missing, the value from the measurements at the closest preceding visit replaced the missing value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.98","spread":"0.75"},{"groupId":"OG001","value":"7.92","spread":"0.82"},{"groupId":"OG002","value":"7.86","spread":"0.83"},{"groupId":"OG003","value":"8.12","spread":"0.78"},{"groupId":"OG004","value":"7.87","spread":"0.75"},{"groupId":"OG005","value":"8.01","spread":"0.64"},{"groupId":"OG006","value":"8.07","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.10","spread":"0.82"},{"groupId":"OG001","value":"7.19","spread":"0.75"},{"groupId":"OG002","value":"7.07","spread":"0.74"},{"groupId":"OG003","value":"7.42","spread":"0.91"},{"groupId":"OG004","value":"6.96","spread":"0.75"},{"groupId":"OG005","value":"7.19","spread":"0.72"},{"groupId":"OG006","value":"6.98","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"0.64"},{"groupId":"OG001","value":"-0.73","spread":"0.65"},{"groupId":"OG002","value":"-0.79","spread":"0.50"},{"groupId":"OG003","value":"-0.70","spread":"0.70"},{"groupId":"OG004","value":"-0.91","spread":"0.61"},{"groupId":"OG005","value":"-0.82","spread":"0.78"},{"groupId":"OG006","value":"-1.09","spread":"0.87"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":82},"commonTop":["Nasopharyngitis","Hypoglycaemia","Fall","Upper respiratory tract inflammation","Contusion"]}}}